A New Name for a Misunderstood Condition: From PCOS to PMOS

If you have ever been told you have polycystic ovary syndrome, there is a decent chance you walked out of that appointment confused. Maybe an ultrasound was normal. Maybe there were no actual cysts. Maybe you were told you had PCOS because of irregular cycles and acne and weight that wouldn't budge, and you spent the next decade trying to find a clinician who understood why the name and the lived experience didn't line up. A May 2026 paper in The Lancet finally calls the question. After a years-long global consensus process involving more than 14,000 patients and 56 medical and patient organisations, polycystic ovary syndrome will now be called polyendocrine metabolic ovarian syndrome, or PMOS.

Photo: Jessica Ching / Unsplash

What the research found

A team led by Helena Teede at Monash University in Australia coordinated the renaming process. The motivation was clinical and ethical, not cosmetic. The term "polycystic ovary syndrome" implies pathological ovarian cysts as the defining feature, yet many women with the diagnosis don't have cysts at all, and the actual ovarian finding is a higher-than-typical number of small follicles. The old name was also obscuring the broader endocrine and metabolic picture: insulin resistance, hyperandrogenism, inflammation, cardiometabolic risk, and fertility implications, all of which deserve clinical attention but get pushed to the background by a name that points at the ovaries alone.

The consensus process was rigorous. Iterative global surveys captured input from 14,360 people with PCOS and multidisciplinary health professionals across world regions. Modified Delphi methods, nominal group technique workshops, and marketing and implementation analyses identified the principles the new name needed to satisfy: scientific accuracy, clarity, stigma avoidance, cultural appropriateness, and feasibility for actual use in clinics and disease classification systems. Three terms emerged as priorities: polyendocrine, metabolic, and ovarian. The new full name, polyendocrine metabolic ovarian syndrome (PMOS), keeps the central message that this is a multisystem condition involving endocrine, metabolic, and ovarian dysfunction. The rollout includes a transition period, professional education, and alignment with health systems and international disease classification.

Where this fits in the wider conversation

The renaming isn't happening in isolation. Recent reviews of PMOS treatment have been expanding the conversation in similar directions. A 2026 narrative review in Drugs by Jensterle and Janez mapped the evidence for incretin-based weight-loss medications, including GLP-1 receptor agonists, in patients with PCOS who carry significant metabolic burden. The authors propose that a multidimensional, metabolic high-risk phenotype is the most rational current target for those medications, while flagging that long-term reproductive, cardiovascular, and pregnancy data are still missing. Their framing matches the consensus paper's central point: this is a metabolic condition with ovarian features at its core, which inverts the long-standing framing.

A 2026 review in Antioxidants added another layer. The authors synthesized current evidence on oxidative stress as a mechanistic link between metabolic and reproductive dysfunction in PCOS/PMOS, and concluded that antioxidant interventions modify redox biomarkers and may improve selected metabolic indices, while noting that consistent effects on hormonal regulation, ovulation, and long-term clinical outcomes remain limited. The authors land on antioxidants as reasonable adjuncts to lifestyle-based management.

The pattern across recent literature is the same: the field is moving away from a single-organ frame and toward a multisystem one. The new name puts the field on the same page.

The naturopathic perspective

Naturopathic medicine has approached PCOS as a metabolic-endocrine condition for a long time. The clinical conversation in most naturopathic offices has centered on insulin sensitivity, blood-sugar regulation, body composition, sleep, stress, gut health, inflammation, and the cascade of hormones (insulin, androgens, LH/FSH, cortisol) that produce the lived experience patients are describing. The new name validates an approach that often had to be explained around the previous name.

What the rename also does, and this matters, is reduce the chance that a woman with significant insulin resistance, irregular cycles, hyperandrogenism, and cardiometabolic risk gets dismissed because her ultrasound looked fine. The old name was operating as a gatekeeper. Clinicians sometimes hesitated to diagnose PCOS without "polycystic" ovaries on imaging, which delayed care for patients whose presentation didn't fit the imaging picture. A name centered on endocrine and metabolic features should help.

The clinical implications stay grounded in the same evidence-based foundations that have always served these patients: blood-sugar stability, resistance training and adequate protein, mind-body work for the chronic stress load that interacts with cortisol and insulin, attention to gut health and inflammation, and where appropriate, the right pharmacological support brought in with intention rather than as a default. Inositol, vitamin D adequacy, omega-3 status, and food quality remain meaningful levers. So does sleep, which sometimes gets the least airtime even though it directly affects insulin sensitivity and androgen patterns.

How to apply this now

If you have a PCOS diagnosis, a few practical points. The condition is the same; the name is what has changed. You may start seeing PMOS show up on lab reports, in clinician notes, and in patient education over the next year or two as the transition rolls out. The diagnostic criteria themselves are evolving alongside the name to better capture the metabolic and endocrine picture. If your symptoms have always felt broader than what the old name implied, that experience matches what the new name reflects.

Practically, the levers haven't changed. Blood-sugar stability across meals matters. Resistance training a few times a week builds the muscle that improves insulin sensitivity over time. Adequate protein, fiber, and broader anti-inflammatory eating patterns help. Sleep matters as much as any supplement. And if you have been carrying significant metabolic risk and weight has not been moving despite consistent effort, the conversation about pharmacological options, including incretin-based medications when clinically appropriate, is reasonable to have with a clinician who understands the full picture. Bringing this condition into balance is mostly about running a coherent plan consistently over time.

If you are newly diagnosed, ask for the full metabolic and endocrine workup, not just an ultrasound. The new framework explicitly invites that broader assessment.

References

1. Teede HJ, Khomami MB, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026. PMID: 42119588. DOI. Original AANP digest link: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext

2. Jensterle M, Janez A. Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map. Drugs. 2026. PMID: 42106472. DOI.

3. Sorić T, Matek Sarić M, Herceg Romanić S, et al. The Role of Antioxidants in the Management of Polycystic Ovary Syndrome. Antioxidants (Basel). 2026;15(4):487. PMID: 42072129. DOI.

A note before you go

This is for educational purposes and is not a substitute for individualized medical care. If you have been diagnosed with PCOS/PMOS, or suspect you might have it, please work with a clinician who can take your full clinical picture into account.

---

If this resonates with what you're experiencing and you'd like to explore a naturopathic approach, book a consultation with our clinic.